...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Just one more thought...I promise!

PVLee "Zenith Capital Corp.spins out Newco in the same manner as RVX Therapeutics was to create Zenith Epiginetics Corp. in 2013. Now if ZCC decides to go public it's going to cost anyone wanting to get on this train big time."

The best estimate I can calc for the current valuation of ZCC would be 67¢ a share.

Share
New Message
Please login to post a reply